Deal-Making

Deal-Making

Seeking to bolster its CDMO business, Bora Pharmaceuticals is acquiring an approximate 30.5% stake in Taiwanese drug maker Tanvex BioPharma.

Facilities & Capacity

The acquisition will increase manufacturing capacity, strengthen commercial service offerings, and expedite the delivery of sterile injectable drug products for clinical and commercial markets, the firm said.

Facilities & Capacity

Merck KGaA’s life science business is the first company to receive such certification for pharmaceutical auxiliary materials (PAMs).

Global Markets

CDMO KBI Biopharma says a lack of capacity demand drove the U-turn on mammalian manufacturing, but the Geneva site will continue to offer other bioproduction services.

Global Markets

The organization will work with vaccine manufacturers to bring much-need doses to Africa.

Regulations

An expert touts the value of written guidance and Explainable AI for establishing industry-wide trust.

Bioprocess Insider

Industry will have to rethink GMP regulations to accommodate AI and ML, says a panel of experts.

Therapeutic Class

Therapeutic Class

The companies say they have capacity to produce 200 million doses and hope to distribute the low-cost vaccine globally to low- and middle-income countries (LMICs).

Upstream & Downstream Processing

Rentschler’s LVV toolbox will offer advanced bioreactor systems, analytical methods for thorough characterization and quality control, and an HEK293 cell line for consistent yields, the firm said.

Therapeutic Class

Experts from Terumo share insights on developing and manufacturing advanced therapies for non-oncological indications.